PEGylated lipids in lipid nanoparticle delivery dynamics and therapeutic innovation

• Peiyang Gao

Beilstein J. Nanotechnol. 2025, 16, 1914–1930, doi:10.3762/bjnano.16.133

• nanoparticle formulation is polyethylene glycol-modified (i.e., PEGylated) lipids (PEG lipids), which can significantly influence the stability, cell interactions, and overall effectiveness of LNP delivery vehicles. This review collates insights into the role of PEG lipids in LNPs by illustrating how the PEG

• , particularly the pathways of anti-PEG antibody production and complement activation. Building on these understandings, functionalized PEG lipids are reviewed for ligand conjugation and targeted LNP delivery function. Promising alternatives to replace the benchmark PEG lipids are also systematically reviewed to

• PEG; immunogenicity; lipid nanoparticles; PEG alternatives; PEG lipids; therapeutic delivery; Review Introduction Lipid nanoparticles (LNPs) have become a promising platform in modern nanomedicine, especially for delivering genetic payloads such as mRNA and siRNA. These nanoscale particles can

Serum heat inactivation diminishes ApoE-mediated uptake of D-Lin-MC3-DMA lipid nanoparticles

• Demian van Straten,
• Luuk van de Schepop,
• Rowan Frunt,
• Pieter Vader and
• Raymond M. Schiffelers

Beilstein J. Nanotechnol. 2025, 16, 740–748, doi:10.3762/bjnano.16.57

• the cell culture media. We initially hypothesized that this difference may have been the result of differences in FCS protein concentrations. Indeed, LNP uptake by HMEC-1 increases with the concentration of (heat treated) FCS (Figure 1A). This is most likely the result of enhanced shedding of PEG

• -lipids from the LNP surface, which needs to occur before a protein corona can be established that allows cellular uptake of LNPs [29]. A difference in FCS protein concentration can thus introduce variations in results when performing experiments with different FCS brands or even different lots of the

Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• , polyethylene glycol (PEG) lipids, and ionizable synthetic lipids (ALC-0315 from BioNTech-Pfizer and SM-102 from Moderna Therapeutics) for enhanced delivery of messenger RNA (mRNA) encoding the spike protein of the SARS-COV-2 virus to antigen-presenting cells [82]. These vaccines were approved by the FDA

Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

• the nanosystems [136][137]. Lipid nanoparticles (LNPs) in clinical trials are mainly composed of ionizable cationic lipids, amphipathic phospholipids, cholesterol, diffusible PEG lipids (for transient protection), and a targeting ligand [138]. After IV administration, lung capillaries receive the

Model systems for studying cell adhesion and biomimetic actin networks

• Dorothea Brüggemann,
• Johannes P. Frohnmayer and
• Joachim P. Spatz

Beilstein J. Nanotechnol. 2014, 5, 1193–1202, doi:10.3762/bjnano.5.131

• with an inert membrane (containing PEG-lipids) is homogeneous and displays a depletion zone underneath the membrane. (B) Liposomes, which contain biotinylated lipids, encapsulate networks of biotinylated actin filaments that are coupled to the membrane via biotin–streptavidin bonds. The scale bars